MoffettNathanson trimmed its target but kept buy; Needham downgraded to hold. Netflix cut its 2026 ad revenue forecast to ...

Ocugen will report Q3 2026 results on 4 November 2026, a checkpoint on its OCU400 timeline and Roots licensing deal.

Western Digital rose 3.9% Wednesday as BofA raised its target to $800 and Morgan Stanley cut to $643, both keeping bullish ...

Bernstein analyst James Hooper reaffirmed a Buy rating on BASF on Tuesday, holding his price target at 61 euros. The ...

BioNTech plans to amend Phase 3 ROSETTA Breast-01 to test pumitamig with Gilead's Trodelvy instead of chemotherapy; the change needs regulatory approval.

About 2,000 trade unionists rallied in Strasbourg against the EU Inc draft, demanding binding guarantees for workers' rights as a committee vote slipped to 5 November.

BP shares sit 1.4% below their 52-week high after a 3.65% Friday gain, as Q3 refining margins nearly doubled and net debt is ...

Plug Power's stock closed Monday at 1.23 euros, hovering just above its 52-week low of 1.21 euros — a valuation that says more about the market's mood on hydrog ...

Moderna shares have been on a tear, and the reasons behind that run are worth separating into what has already happened and ...

Ocugen confirmed 140 patients enrolled in the liMeliGhT Phase 3 trial of OCU400, with the primary endpoint now measured using ...

IonQ shares climbed 8.7% in yesterday's session, riding a rebound across quantum computing names that followed a selloff ...

TSMC has attached a firm condition to any further American manufacturing footprint: whoever builds the chips, TSMC runs the ...